Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer: The role of clinical response

European Journal of Cancer

Volumn 39, Issue 8, 2003, Pages 1089-1096

  Pierga, J Y ^a   Mouret, E ^a   Laurence, V ^a   Dieras V ^a   Savigioni, A ^a   Beuzeboc, P ^a   Dorval, T ^a   Palangie T ^a   Jouve, M ^a   Pouillart, P ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Prognostic factor

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; PROGESTERONE RECEPTOR; THIOTEPA;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0038740871     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00069-8     Document Type: Article

References (42)

1. Hortobagyi G.N., Buzdar A.U., Strom E.A., Ames F.C., Singletary S.E. Primary chemotherapy for early and advanced breast cancer. Cancer Lett. 90:1995;103-109.
2. Kuerer H.M., Hunt K.K., Newman L.A., Ross M.I., Ames F.C., Singletary S.E. Neoadjuvant chemotherapy in women with invasive breast carcinoma. conceptual basis and fundamental surgical issues J. Am. Coll. Surg. 190:2000;350-363.
3. Scholl S.M., Fourquet A., Asselain B.et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery. preliminary results of a randomised trial: S6 Eur. J. Cancer. 30A:1994;645-652.
4. Semiglazov V.F., Topuzov E.E., Bavli J.L.et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann. Oncol. 5:1994;591-595.
5. Powles T.J., Hickish T.F., Makris A.et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J. Clin. Oncol. 13:1995;547-552.
6. Fisher B., Bryant J., Wolmark N.et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16:1998;2672-2685.
7. Mauriac L., MacGrogan G., Avril A.et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm. a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS) Ann. Oncol. 10:1999;47-52.
8. van der Hage J.A., van de Velde C.J., Julien J.P., Tubiana-Hulin M., Vandervelden C., Duchateau L. Preoperative chemotherapy in primary operable breast cancer. results from the European Organization for Research and Treatment of Cancer trial 10902 J. Clin. Oncol. 19:2001;4224-4237.
9. Broet P., Scholl S.M., de la Rochefordiere A.et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy. an updated analysis of a randomized trial Breast Cancer Res. Treat. 58:1999;151-156.
10. Fisher B., Brown A., Mamounas E.et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer. findings from National Surgical Adjuvant Breast and Bowel Project B-18 J. Clin. Oncol. 15:1997;2483-2493.
11. Rouzier R., Extra J.M., Carton M.et al. Primary chemotherapy for operable breast cancer. incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery J. Clin. Oncol. 19:2001;3828-3835.
12. Pierga J.Y., Girre V., Beuzeboc P.et al. Randomised trial of neoadjuvant chemotherapy in operable breast cancer comparing Adriamycin-Cyclophosphamide (CPM)- 5FU (ACF) versus Thiotepa- CPM- 5FU (TCF). Ann. Oncol. 11(Suppl. 4):2000;24. (abstr).
13. Pierga J.Y., Mouret E., Dieras V.et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br. J. Cancer. 83:2000;1480-1487.
14. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:1966;163-170.
16. Cox D.R. Regression models and life tables. J. Stat. Soc. B. 34:1972;187-220.
17. Fisher B., Mamounas E.P. Preoperative chemotherapy. a model for studying the biology and therapy of primary breast cancer J. Clin. Oncol. 13:1995;537-540.
18. Mamounas E.P., Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin. Oncol. 28:2001;389-399.
19. Scholl S.M., Pierga J.Y., Asselain B.et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur. J. Cancer. 31A:1995;1969-1975.
20. Jacquillat C., Weil M., Borel C.et al. [Tumor regression as a prognostic factor in breast cancer]. Bull. Cancer. 78:1991;435-443.
21. Cameron D.A., Anderson E.D., Levack P.et al. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. Br. J. Cancer. 76:1997;1099-1105.
22. Hortobagyi G.N., Buzdar A.U., Kau S.W.et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 62:1988;2507-2516.
23. Ellis P., Smith I., Ashley S., Walsh G.et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J. Clin. Oncol. 16:1998;107-114.
24. Feldman L.D., Hortobagyi G.N., Buzdar A.U., Ames F., Blumenschein G. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 46:1986;2578-2581.
25. Sataloff D.M., Mason B.A., Prestipino A.J., Seinige U.L., Lieber C.P., Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast. a determinant of outcome J. Am. Coll. Surg. 180:1995;297-306.
26. Kuerer H.M., Sahin A.A., Hunt K.K.et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann. Surg. 230:1999;72-78.
27. Bonadonna G., Valagussa P., Brambilla C.et al. Primary chemotherapy in operable breast cancer. eight-year experience at the Milan Cancer Institute J. Clin. Oncol. 16:1998;93-100.
28. Chevallier B., Chollet P., Merrouche Y.et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J. Clin. Oncol. 13:1995;1564-1571.
29. Honkoop A.H., Pinedo H.M., De Jong J.S.et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am. J. Clin. Pathol. 107:1997;211-218.
30. Costa S.D., von Minckwitz G., Raab G.et al. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin. Oncol. 26(Suppl. 9):1999;24-31.
31. Smith I.C., Heys S.D., Hutcheon A.W.et al. Neoadjuvant chemotherapy in breast cancer. significantly enhanced response with docetaxel J. Clin. Oncol. 20:2002;1456-1466.
32. Machiavelli M.R., Romero A.O., Perez J.E.et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J. Sci. Am. 4:1998;125-131.
33. Herrada J., Iyer R.B., Atkinson E.N., Sneige N., Buzdar A.U., Hortobagyi G.N. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumour and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin. Cancer Res. 3:1997;1565-1569.
34. Buchholz T.A., Hill B.S., Tucker S.L.et al. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 7:2001;413-420.
35. Hayes D.F., Trock B., Harris A.L. Assessing the clinical impact of prognostic factors. when is "statistically significant" clinically useful? Breast Cancer Res. Treat. 52:1998;305-319.
36. Smith I.E., Walsh G., Jones A.et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J. Clin. Oncol. 13:1995;424-429.
37. von Minckwitz G., Costa S.D., Eiermann W.et al. Maximized reduction of primary breast tumor size using preperative chemotherapy with doxorubicin and docetaxel. J. Clin. Oncol. 17:1999;1999-2005.
38. The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide. preliminary results from NSABP Protocol B-27 Breast Cancer Res. Treat. 2001;. (abstr).
39. Hutcheon A.W., Heys S.D., Miller I.D.et al. Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer. a randomised controlled trial Breast Cancer Res. Treat. 2001;. (abstr).
40. Antman K.H. A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer. Eur. J. Cancer. 37:2001;173-179.
41. Remvikos Y., Beuzeboc P., Zajdela A., Voillemot N., Magdelenat H., Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J. Natl. Cancer Inst. 81:1989;1383-1387.
42. Diéras V., Jouve M., Asselain B.et al. S-phase fraction (SPF) and response to primary chemotherapy (CT) for breast cancer (BC). predictive factor for response but poor prognostic factor for survival Proc. Am. Soc. Clin. Oncol. 16:1997;140.